Clinical trials: Cognitive Function in Elderly
Cognitive Change
CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women
The investigators propose to conduct the present study in order to primarily assess the effects of CMI-168 in neurocognition enhancement.
- Trial name
- NCT03612752
- Testing
- CMI-168
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Cerebos Pacific Limited
Mild Cognitive Impairment, So Stated, Mild Dementia
Cognitive/Physical Computer-Game Blended Training With Personalized Brain Network Activation Technology for the Elderly
The study involves a novel Virtual Reality Interface that offers full-body immersion "Alterniity AR" and more specifically computer exercises blended with game activities.
- Conditions
- Mild Cognitive Impairment, So Stated, Mild Dementia, Healthy
- Trial name
- AlterniityAR (NCT02417558)
- Testing
- Alterniity Augmented Reality (AAR), VideoGrade
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- XtremeVRI AG
Cognitive Dysfunction, Schizophrenia
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356.
- Trial name
- NCT06225115
- Testing
- KYN-5356
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Kynexis B.V.
Alzheimer Disease, Dementia
ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE
In 1906, Dr. Alois Alzheimer first described the disease that later took his name. Today, 100 years later, 24 million people worldwide suffer from Alzheimer's disease or other dementias.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Disorders
- Trial name
- ADVANCE (NCT01772095)
- Where
- Greece
- Volunteers
- 389 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Hyponatremia
Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.
- Trial name
- INSIGHT (NCT00550459)
- Testing
- Tolvaptan
- Where
- 12 sites in United States
- Volunteers
- 57 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive…
- Trial name
- NCT02546310
- Testing
- HTL0009936
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Risk Behavior, Cognitive Decline
Multidomain Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help middle-aged to older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors…
- Trial name
- NCT05141578
- Testing
- Luci Coach Assisted Intervention
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- LuciLab
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.
- Trial name
- NCT00754013
- Testing
- Aricept (Donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Healthy Volunteers
Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
The purpose of this study is to evaluate the effects of etifoxine (an anxiolytic) compared to lorazepam (a benzodiazepine anxiolytic) on vigilance and cognitive functions in the elderly.
- Trial name
- NCT02147548
- Testing
- etifoxine, lorazepam
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Biocodex
Mild Cognitive Impairment, Alzheimer's Disease
A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain.
- Trial name
- XanaMIA-DR (NCT04983368)
- Testing
- Xanamem® 5 mg, Xanamem® 10 mg
- Where
- 5 sites in Australia
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical
Irritable Bowel Syndrome
MHNA-001 for Young Adults With IBS
The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ IBS together with care as usual in approximately 100 young adults with Irritable Bowel Syndrome.
- Trial name
- NCT05333926
- Testing
- MHNA-001
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Mahana Therapeutics
Memory, Cognition
Effects Of Detrol LA On Memory And Cognition In Elderly Population
The primary purpose of the trial is to show that tolterodine ER has no effect on memory and other cognitive abilities in an elderly population
- Trial name
- NCT00411437
- Testing
- Tolterodine ER, Oxybutynin ER
- Where
- 9 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Alzheimer's Disease, Huntington's Disease
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.
- Trial name
- NCT00990613
- Testing
- Dimebon IR, Dimebon Transdermal
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented
A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented
- Trial name
- NCT05702177
- Testing
- Daridorexant 25 mg, Daridorexant 50 mg
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Alzheimer Disease, Mild Cognitive Impairment
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognition Disorders in Old Age
- Trial name
- AlzLife (NCT03657745)
- Testing
- Combination of 40Hz light and cognitive therapy (ALZLIFE)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Cognitive Impairment, Mild
Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects With Cognitive Impairment
A randomized, double-blind, placebo-controlled, two arm cross-over study to determine whether a specific combination of Andrographis paniculata and Withania somnifera can be regarded as a safe and effective treatment for…
- Trial name
- NCT03780621
- Testing
- Andrographis and Withania
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- EuroPharma, Inc.
Dementia, Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
- Trial name
- NCT00216593
- Testing
- galantamine hydrobromide
- Volunteers
- 415 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Down Syndrome
Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30
To evaluate the suitability (i.e. number of tests completed and number of participants completing the tests, variance estimate of baseline and of the change from baseline values) of neurocognitive tests and functioning scales in…
- Trial name
- NCT02431117
- Where
- 7 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Chugai Pharmaceutical
Risk Behavior, Cognitive Decline
Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors associated with…
- Trial name
- NCT04616794
- Testing
- Cognitive Engagement Group, Physical Activity Group, Diet Group
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- LuciLab
Dementia, Alzheimer's Disease and Related Dementias
HomeCare Medication Management for People With Dementia
This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.
- Trial name
- NCT07872072
- Testing
- HomeCare
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- HiDO Technologies